Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs.
Featured News
Calquence significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukaemia
An encouraging 88% of patients on Calquence remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine
Our Science
Drug Discovery
Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create a range of highly selective therapies for cancer.
Innovative Clinical Studies
Working together Acerta and AstraZeneca are focused on Innovative Clinical Strategies to enable us to combine our extensive oncology portfolio of cancer therapies.
Resistance Biology
Our multiparametric phospho-proteomic platform enables the characterization of activated signaling networks within complex tissues and in discrete cell subsets.
Translational Medicine
Our Translational Medicine (TM) team are actively implementing MRD endpoints in our clinical trials to understand what treatments can drive to MRD undetectable levels.
Research in the Netherlands
At our recently expanded site at Oss in the Netherlands, we have core capabilities in target identification, target validation, lead generation and compound optimization. The Oss research centre is based in the heart of the Pivot Park Biotechnology Campus and has established relationships with both academic and commercial partners in Europe.